Institutional members access full text with Ovid®

Share this article on:

Respiratory Syncytial Virus Prophylaxis in a High-Risk Population in Argentina: A Cost-Effectiveness Analysis

Rodríguez, Susana P. MD*; Fariña, Diana MD*; Bauer, Gabriela MD†

Pediatric Infectious Disease Journal: July 2008 - Volume 27 - Issue 7 - pp 660-661
doi: 10.1097/INF.0b013e3181691753
Brief Reports

Palivizumab has proved effective in reducing hospitalization rates because of respiratory syncytial virus in vulnerable groups. In Argentina its administration is not universal because of high costs. We made a cohort study and enrolled 159 children who met the American Academy of Pediatrics recommendations but did not receive palivizumab; 26% required hospitalization for respiratory syncytial virus infection. Siblings and bronchopulmonary dysplasia were associated with higher hospitalization. For high-risk patients, one averted hospitalization was associated with costs of U.S. dollars (USD)13, 198 [number needed to treat (NNT): 4.5].

From the *Neonatal Intensive Care Unit; and †High Risk Clinic Follow-Up Program, Hospital de Pediatría, “Prof. Dr. J. P. Garrahan”, Buenos Aires, Argentina.

Accepted for publication January 16, 2008.

Address for correspondence: Susana Rodriguez, MD, Ceretti 1836 (1431) Buenos Aires, Argentina. E-mail: susiro@ciudad.com.ar; sprodriguez@garrahan.gov.ar.

© 2008 Lippincott Williams & Wilkins, Inc.